Study of establishing disease-syndrome combined with animal model for immune thrombocytopenic purpura without additional conditions

Abstract

ObjectiveTo explore the feasibility of establishing the disease-syndrome combined animal model for immune thrombocytopenic purpura (ITP) without additional conditions. MethodsThree batches of data related to the ITP model mice obtained by replication at different time were analyzed, and whether the APS-injected model mice replicated through the passive immune modeling method could simulate the pathogenesis and clinical characteristics of human ITP was evaluated according to the differentiation criteria for disease-syndrome combined model. ResultsThe APS-injected replicated ITP model mice possessed the following traits: (1) Compared with the normal group, the platelet count was significantly decreased, and coagulation time was significantly increased in the model group (P < .01). (2) Compared with the normal group, the medullary thrombocytogenous megakaryocytes were significantly decreased (P < .05, .01, .001). (3) The APS-injected sites and other parts of the model mice had spontaneous hemorrhage. (4) Behavioral changing signs were observed 1 week after the modeling (i.e. low activity, delayed activity, poor appetite, skin petechia/hemorrhage and spontaneous hemorrhage at the injected sites or other parts), and were getting more and more severe. ConclusionAccording to the syndrome differentiation criteria for disease-syndrome combined model of ITP, the APS-injected animal model of ITP replicated through the passive immune modeling method without additional conditions possesses the characteristics of disease-syndrome combined model. It provides an ideal tool for the development of traditional Chinese medicine pharmacology experiment.